<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01890122</url>
  </required_header>
  <id_info>
    <org_study_id>SYR-322MET_303</org_study_id>
    <secondary_id>U1111-1139-0497</secondary_id>
    <secondary_id>NMRR-12-799-12754</secondary_id>
    <secondary_id>CTR20130254</secondary_id>
    <secondary_id>1036022140</secondary_id>
    <nct_id>NCT01890122</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin and Metformin Fixed Dose Combination, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of alogliptin and metformin
      fixed-dose combination (FDC) as compared with alogliptin alone or metformin alone on Type 2
      Diabetes Mellitus (T2DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is a fixed-dose combination tablet of alogliptin and
      metformin to treat people who have diabetes. This study will look at glycemic control in
      people who take alogliptin and metformin FDC compared with alogliptin or metformin alone. The
      study will enroll approximately 640 patients. Participants will be randomly assigned (by
      chance, like flipping a coin) to one of the four treatment groups—which will remain
      undisclosed to the participant and study doctor during the study (unless there is an urgent
      medical need):

        -  Alogliptin 12.5 mg twice daily (BID)

        -  Metformin hydrochloride (HCl) 500 mg BID

        -  Alogliptin 12.5 mg and Metformin HCl 500 mg FDC BID

        -  Placebo (dummy inactive pill) - this is a tablet/capsule that looks like the study drug
           but has no active ingredient.

      All participants will be asked to take 2 tablets and 1 capsule twice a day at the same time
      each day throughout the study. All participants will be asked to record any hypoglycemic
      events in a diary. This multi-center trial will be conducted in China, South Korea, Taiwan
      and Malaysia. The overall time to participate in this study is 34 weeks. Participants will
      make 11 visits to the clinic.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination)</measure>
    <time_frame>Baseline and Week 26 (or Early termination)</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 26 or early termination relative to baseline. Negative change indicates better glycemic control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c at Weeks 4, 8, 12, 16 and 20</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16 and 20</time_frame>
    <description>The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Weeks 4, 8, 12, 16 and 20 relative to baseline. Negative change indicates better glycemic control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 8, 12, 16, 20 and 26</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26</time_frame>
    <description>The change between the FPG value collected at Weeks 4, 8, 12, 16, 20 and 26 relative to baseline. Negative change indicates better glycemic control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hyperglycemic Rescue Event</measure>
    <time_frame>From the date of randomization through Week 26</time_frame>
    <description>Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After &gt;1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline. Time to hyperglycemic rescue was censored if the participant did not experience a hyperglycemic rescue event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Hyperglycemic Rescue</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After &gt;1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Marked Hyperglycemia</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Marked hyperglycemia is defined as FPG level ≥200 mg/dL (11.1 mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Weeks 12 and 26</measure>
    <time_frame>Baseline and Weeks 12 and 26</time_frame>
    <description>Change in participant's body weight at Weeks 12 and 26 relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Glycosylated Hemoglobin ≤6.5%</measure>
    <time_frame>Week 26</time_frame>
    <description>Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤6.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Glycosylated Hemoglobin ≤7.0%</measure>
    <time_frame>Week 26</time_frame>
    <description>Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Glycosylated Hemoglobin ≤7.5%</measure>
    <time_frame>Week 26</time_frame>
    <description>Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥0.5%</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥0.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.0%</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.5%</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥2.0%</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥2.0%.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">647</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin HCl 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 12.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin</intervention_name>
    <description>Alogliptin tablets</description>
    <arm_group_label>Alogliptin 12.5 mg</arm_group_label>
    <other_name>SYR-322; Nesina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin HCl</intervention_name>
    <description>Metformin HCl capsules</description>
    <arm_group_label>Metformin HCl 500 mg</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin and Metformin Fixed-Dose Combination (FDC)</intervention_name>
    <description>Alogliptin and metformin FDC tablets</description>
    <arm_group_label>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</arm_group_label>
    <other_name>Kazano</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin Placebo</intervention_name>
    <description>Alogliptin placebo-matching tablets</description>
    <arm_group_label>Metformin HCl 500 mg</arm_group_label>
    <arm_group_label>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Placebo</intervention_name>
    <description>Metformin placebo-matching capsules</description>
    <arm_group_label>Alogliptin 12.5 mg</arm_group_label>
    <arm_group_label>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin and Metformin FDC Placebo</intervention_name>
    <description>Alogliptin and metformin FDC placebo-matching tablets</description>
    <arm_group_label>Metformin HCl 500 mg</arm_group_label>
    <arm_group_label>Alogliptin 12.5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Capable of understanding and complying with protocol requirements.

          2. The participant or, when applicable, the participant's legally acceptable
             representative signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          3. Has a historical diagnosis of Type 2 diabetes mellitus (T2DM).

          4. Male or female and aged 18 to 75 years, inclusive.

          5. Body mass index (BMI) between 20 and 45 kg/m^2, inclusive.

          6. A female of childbearing potential who is sexually active with a nonsterilized male
             partner agrees to use routinely adequate contraception from signing of informed
             consent throughout the duration of the study.

          7. Is experiencing inadequate glycemic control defined as glycosylated hemoglobin (HbA1c)
             concentration between 7.5% and 10%, inclusive, and has been treated with diet and
             exercise for at least 2 months prior to Screening. (Exception: a participant who has
             received any other diabetic therapy for less than 7 days in total within the 2 months
             prior to the screening, can be included).

          8. If male, has a hemoglobin &gt;12 g/dL (&gt;120 g/L) at Screening or if female, has a
             hemoglobin &gt;10 g/dL (&gt;100 g/L) at Screening.

          9. If male, has a serum creatinine &lt;1.5 mg/dL at Screening or if female, has a serum
             creatinine &lt;1.4 mg/dL at Screening, and estimated glomerular filtration rate (eGFR)
             &gt;60 mL/min/1.73 m^2 based on calculation using the Modification of Diet in Renal
             Disease (MDRD) at Screening.

         10. Willing and able to monitor their own blood glucose concentrations using a home
             glucose monitor and complete a subject diary.

        Exclusion Criteria:

          1. Participated in another clinical study within 90 days prior to Screening.

          2. Received any investigational compound within 30 days prior to Randomization.

          3. Received a dipeptidyl peptidase-4 (DPP-4) inhibitor within 3 months prior to
             screening.

          4. History of laser treatment for proliferative diabetic retinopathy within the 6 months
             prior to Screening.

          5. History of treatment for diabetic gastric paresis, gastric banding, or gastric bypass
             surgery.

          6. History of diabetic ketoacidosis or hyperosmolar non-ketotic coma.

          7. Chronic pancreatitis and/or history of acute pancreatitis.

          8. Systolic blood pressure &gt;180 mm Hg and/or diastolic blood pressure &gt;110 mm Hg at
             Screening.

          9. History of any hemoglobinopathy or diagnosis of chronic anemia.

         10. New York Heart Association Class III or IV heart failure. (Participants who are stable
             at Class I or II and are currently treated, are candidates for the study.)

         11. History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or
             myocardial infarction within 6 months prior to Screening.

         12. History of any cancer, other than squamous cell or basal cell carcinoma of the skin,
             which has not been in full remission for at least 5 years prior to Screening.
             Participants with a history of treated cervical intraepithelial neoplasia [CIN] I or
             CIN II are allowed.

         13. Significant clinical sign or symptom of hepatopathy, acute or chronic hepatitis, human
             immunodeficiency virus or alanine aminotransferase (ALT) is 2.5 times above upper
             limit of normal value.

         14. History of angioedema in association with use of angiotensin-converting enzyme
             inhibitors (ACEI) or angiotensin II receptor blockers (ARB).

         15. History of hypersensitivity or allergies to any DPP-4 inhibitor and/or metformin or
             related compounds.

         16. Has used oral or systemically injected glucocorticoids (including intra-articular
             injection) or has used weight-loss drugs within 2 months prior to Screening. (Inhaled
             or topical corticosteroids were allowed.)

         17. History of alcohol or substance abuse within 2 years prior to Screening.

         18. Has used medicine for weight loss within 60 days prior to Screening (such as Xenical,
             Sibutramine, Phenylpropanolamine or similar nonprescription drugs).

         19. History of organ transplantation.

         20. Is an immediate family member, study site employee, or is in a dependant relationship
             with a study site employee who is involved in conduct of this study (eg, spouse,
             parent, child, sibling) or may consent under duress.

         21. Has, in the judgment of the investigator, any major illness or debility that may
             prohibit the participant from completing the study.

         22. If female, is pregnant or lactating or intending to become pregnant before, during, or
             within 1 month after participating in this study; or intending to donate ova during
             such time period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hengshui</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shiyan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yueyang</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johor Bahru</city>
        <state>Johor</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alor Setar</city>
        <state>Kedah Darul Aman</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alor Setar</city>
        <state>Kedah</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kubang Kerian</city>
        <state>Kelantan</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nilai</city>
        <state>Negeri Sembilan</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seremban</city>
        <state>Negeri Sembilan</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampin</city>
        <state>Negeri Sembilan</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bagan Serai</city>
        <state>Perak</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ipoh</city>
        <state>Perak</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petaling Jaya</city>
        <state>Selangor</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shah Alam</city>
        <state>Selangor</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Putrajaya</city>
        <state>WIlayah Persekutuan</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203414s000lbl.pdf</url>
    <description>The Alogliptin-Metformin Fixed Dose Combination (KAZANO) were approved in the United States (US) on 25 January 2013.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2013</study_first_posted>
  <results_first_submitted>October 4, 2016</results_first_submitted>
  <results_first_submitted_qc>October 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 28, 2016</results_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alogliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 59 investigative sites in China, Malaysia, South Korea and Taiwan from 26 August 2013 to 05 October 2015.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of type 2 diabetes mellitus were enrolled equally in 1 of 4 treatment groups, twice a day placebo, alogliptin 12.5 mg, metformin hydrochloride (HCl) 500 mg, or alogliptin 12.5 mg and metformin HCl 500 mg fixed dose combination (FDC).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin HCl 500 mg</title>
          <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Alogliptin 12.5 mg</title>
          <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
          <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="162">Started = Enrolled set which included all participants who signed informed consent.</participants>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="159"/>
                <participants group_id="P4" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="161">Treated = Randomized participants who received at least one dose of study drug.</participants>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="159"/>
                <participants group_id="P4" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="146"/>
                <participants group_id="P4" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized set consisted of all enrolled participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Metformin HCl 500 mg</title>
          <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Alogliptin 12.5 mg</title>
          <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
          <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
            <count group_id="B2" value="163"/>
            <count group_id="B3" value="159"/>
            <count group_id="B4" value="163"/>
            <count group_id="B5" value="647"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="9.91"/>
                    <measurement group_id="B2" value="55.4" spread="9.62"/>
                    <measurement group_id="B3" value="53.4" spread="10.46"/>
                    <measurement group_id="B4" value="52.2" spread="10.17"/>
                    <measurement group_id="B5" value="53.6" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="161"/>
                    <measurement group_id="B5" value="643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino (Yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino (No)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="163"/>
                    <measurement group_id="B5" value="646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163.8" spread="8.72"/>
                    <measurement group_id="B2" value="165.0" spread="8.06"/>
                    <measurement group_id="B3" value="164.3" spread="7.66"/>
                    <measurement group_id="B4" value="164.2" spread="9.19"/>
                    <measurement group_id="B5" value="164.3" spread="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Weight data is available for 161, 163, 159 and 163 participants in each treatment arm, respectively.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.79" spread="12.357"/>
                    <measurement group_id="B2" value="71.21" spread="11.669"/>
                    <measurement group_id="B3" value="70.73" spread="11.489"/>
                    <measurement group_id="B4" value="71.79" spread="13.949"/>
                    <measurement group_id="B5" value="71.13" spread="12.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.30" spread="3.566"/>
                    <measurement group_id="B2" value="26.16" spread="3.923"/>
                    <measurement group_id="B3" value="26.16" spread="3.508"/>
                    <measurement group_id="B4" value="26.56" spread="4.218"/>
                    <measurement group_id="B5" value="26.30" spread="3.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Has Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="112"/>
                    <measurement group_id="B5" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Is a Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Is an Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Female Reproductive Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgically Sterile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female of Childbearing Potential</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Applicable (Participant is Male)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="130"/>
                    <measurement group_id="B5" value="516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan, Province of China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination)</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 26 or early termination relative to baseline. Negative change indicates better glycemic control.</description>
        <time_frame>Baseline and Week 26 (or Early termination)</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination)</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 26 or early termination relative to baseline. Negative change indicates better glycemic control.</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="1.067"/>
                    <measurement group_id="O2" value="-1.23" spread="0.877"/>
                    <measurement group_id="O3" value="-1.06" spread="0.970"/>
                    <measurement group_id="O4" value="-1.72" spread="1.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>An analysis of covariance (ANCOVA) model was used with treatment and country as fixed effects, and Baseline HbA1c as a continuous covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.700</ci_lower_limit>
            <ci_upper_limit>-0.278</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>An ANCOVA model was used with treatment and country as fixed effects, and Baseline HbA1c as a continuous covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.108</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.889</ci_lower_limit>
            <ci_upper_limit>-0.467</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c at Weeks 4, 8, 12, 16 and 20</title>
        <description>The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Weeks 4, 8, 12, 16 and 20 relative to baseline. Negative change indicates better glycemic control.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16 and 20</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Weeks 4, 8, 12, 16 and 20</title>
          <description>The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Weeks 4, 8, 12, 16 and 20 relative to baseline. Negative change indicates better glycemic control.</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=157,156,154,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.483"/>
                    <measurement group_id="O2" value="-0.41" spread="0.570"/>
                    <measurement group_id="O3" value="-0.80" spread="0.489"/>
                    <measurement group_id="O4" value="-0.18" spread="0.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=160,160,158,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="0.682"/>
                    <measurement group_id="O2" value="-0.78" spread="0.756"/>
                    <measurement group_id="O3" value="-1.29" spread="0.732"/>
                    <measurement group_id="O4" value="-0.29" spread="0.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=160,160,158,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" spread="0.793"/>
                    <measurement group_id="O2" value="-1.01" spread="0.839"/>
                    <measurement group_id="O3" value="-1.57" spread="0.873"/>
                    <measurement group_id="O4" value="-0.27" spread="0.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=160,160,158,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="0.816"/>
                    <measurement group_id="O2" value="-1.06" spread="0.900"/>
                    <measurement group_id="O3" value="-1.71" spread="0.937"/>
                    <measurement group_id="O4" value="-0.33" spread="0.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=160.160,158,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="0.852"/>
                    <measurement group_id="O2" value="-1.11" spread="0.925"/>
                    <measurement group_id="O3" value="-1.74" spread="0.969"/>
                    <measurement group_id="O4" value="-0.33" spread="1.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 8, 12, 16, 20 and 26</title>
        <description>The change between the FPG value collected at Weeks 4, 8, 12, 16, 20 and 26 relative to baseline. Negative change indicates better glycemic control.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 8, 12, 16, 20 and 26</title>
          <description>The change between the FPG value collected at Weeks 4, 8, 12, 16, 20 and 26 relative to baseline. Negative change indicates better glycemic control.</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=157,154,155,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="1.344"/>
                    <measurement group_id="O2" value="-1.01" spread="1.794"/>
                    <measurement group_id="O3" value="-2.01" spread="2.157"/>
                    <measurement group_id="O4" value="0.02" spread="1.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=160,158,158,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="1.571"/>
                    <measurement group_id="O2" value="-1.17" spread="1.788"/>
                    <measurement group_id="O3" value="-2.13" spread="1.808"/>
                    <measurement group_id="O4" value="-0.08" spread="1.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=160,158,158,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="1.527"/>
                    <measurement group_id="O2" value="-1.33" spread="1.938"/>
                    <measurement group_id="O3" value="-2.14" spread="1.779"/>
                    <measurement group_id="O4" value="-0.08" spread="2.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=160,158,158,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.62" spread="1.599"/>
                    <measurement group_id="O2" value="-1.25" spread="2.148"/>
                    <measurement group_id="O3" value="-2.17" spread="1.923"/>
                    <measurement group_id="O4" value="-0.07" spread="2.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=160,158,158,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="1.634"/>
                    <measurement group_id="O2" value="-1.19" spread="2.248"/>
                    <measurement group_id="O3" value="-2.26" spread="1.995"/>
                    <measurement group_id="O4" value="-0.12" spread="2.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=160,158,158,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="1.674"/>
                    <measurement group_id="O2" value="-1.06" spread="2.307"/>
                    <measurement group_id="O3" value="-2.06" spread="2.274"/>
                    <measurement group_id="O4" value="-0.04" spread="2.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hyperglycemic Rescue Event</title>
        <description>Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After &gt;1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline. Time to hyperglycemic rescue was censored if the participant did not experience a hyperglycemic rescue event.</description>
        <time_frame>From the date of randomization through Week 26</time_frame>
        <population>Randomized set consisted of all enrolled participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hyperglycemic Rescue Event</title>
          <description>Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After &gt;1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline. Time to hyperglycemic rescue was censored if the participant did not experience a hyperglycemic rescue event.</description>
          <population>Randomized set consisted of all enrolled participants who were randomized.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not estimable as fewer than 50% of participants in any arm required hyperglycemic rescue.</measurement>
                    <measurement group_id="O2" value="NA">Data was not estimable as fewer than 50% of participants in any arm required hyperglycemic rescue.</measurement>
                    <measurement group_id="O3" value="NA">Data was not estimable as fewer than 50% of participants in any arm required hyperglycemic rescue.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="113.0">Data was not estimable as fewer than 50% of participants in any arm required hyperglycemic rescue.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Hyperglycemic Rescue</title>
        <description>Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After &gt;1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline.</description>
        <time_frame>Baseline up to Week 26</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Hyperglycemic Rescue</title>
          <description>Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After &gt;1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline.</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="14.8"/>
                    <measurement group_id="O3" value="4.4"/>
                    <measurement group_id="O4" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Marked Hyperglycemia</title>
        <description>Marked hyperglycemia is defined as FPG level ≥200 mg/dL (11.1 mmol/L).</description>
        <time_frame>Baseline up to Week 26</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Marked Hyperglycemia</title>
          <description>Marked hyperglycemia is defined as FPG level ≥200 mg/dL (11.1 mmol/L).</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="12.7"/>
                    <measurement group_id="O3" value="5.7"/>
                    <measurement group_id="O4" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Weeks 12 and 26</title>
        <description>Change in participant's body weight at Weeks 12 and 26 relative to baseline.</description>
        <time_frame>Baseline and Weeks 12 and 26</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Weeks 12 and 26</title>
          <description>Change in participant's body weight at Weeks 12 and 26 relative to baseline.</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=153,151,149,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="1.735"/>
                    <measurement group_id="O2" value="-0.19" spread="1.696"/>
                    <measurement group_id="O3" value="-0.14" spread="1.730"/>
                    <measurement group_id="O4" value="-0.32" spread="1.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=156,156,156,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="2.240"/>
                    <measurement group_id="O2" value="-0.22" spread="2.291"/>
                    <measurement group_id="O3" value="-0.57" spread="2.336"/>
                    <measurement group_id="O4" value="-0.33" spread="2.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Glycosylated Hemoglobin ≤6.5%</title>
        <description>Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤6.5%.</description>
        <time_frame>Week 26</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Glycosylated Hemoglobin ≤6.5%</title>
          <description>Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤6.5%.</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="21.6"/>
                    <measurement group_id="O3" value="55.1"/>
                    <measurement group_id="O4" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Glycosylated Hemoglobin ≤7.0%</title>
        <description>Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7%.</description>
        <time_frame>Week 26</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Glycosylated Hemoglobin ≤7.0%</title>
          <description>Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7%.</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9"/>
                    <measurement group_id="O2" value="44.4"/>
                    <measurement group_id="O3" value="77.2"/>
                    <measurement group_id="O4" value="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Glycosylated Hemoglobin ≤7.5%</title>
        <description>Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7.5%.</description>
        <time_frame>Week 26</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Glycosylated Hemoglobin ≤7.5%</title>
          <description>Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7.5%.</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="60.5"/>
                    <measurement group_id="O3" value="84.8"/>
                    <measurement group_id="O4" value="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥0.5%</title>
        <description>Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥0.5%.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥0.5%</title>
          <description>Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥0.5%.</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4"/>
                    <measurement group_id="O2" value="74.1"/>
                    <measurement group_id="O3" value="89.2"/>
                    <measurement group_id="O4" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.0%</title>
        <description>Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.0%.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.0%</title>
          <description>Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.0%.</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4"/>
                    <measurement group_id="O2" value="53.7"/>
                    <measurement group_id="O3" value="83.5"/>
                    <measurement group_id="O4" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.5%</title>
        <description>Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.5%.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.5%</title>
          <description>Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.5%.</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="62.0"/>
                    <measurement group_id="O4" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥2.0%</title>
        <description>Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥2.0%.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin HCl 500 mg</title>
            <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
            <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥2.0%</title>
          <description>Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥2.0%.</description>
          <population>Full analysis set consisted of all randomized participants in the safety set (participants who received at least 1 dose of study drug) who had baseline and at least 1 post baseline assessment. LOCF imputation was utilized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="17.3"/>
                    <measurement group_id="O3" value="34.8"/>
                    <measurement group_id="O4" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 1 up to Week 28</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment. Safety set, all participants who took at least 1 dose of double-blind study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Metformin HCl 500 mg</title>
          <description>Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Alogliptin 12.5 mg</title>
          <description>Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Alogliptin 12.5 mg + Metformin HCl 500 mg FDC</title>
          <description>Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <description>One treatment-emergent death occurred during treatment with placebo and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

